These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 7993834)
1. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078 [TBL] [Abstract][Full Text] [Related]
3. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077 [TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076 [TBL] [Abstract][Full Text] [Related]
6. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079 [TBL] [Abstract][Full Text] [Related]
7. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974 [TBL] [Abstract][Full Text] [Related]
8. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081 [TBL] [Abstract][Full Text] [Related]
9. Suramin: rapid loading and weekly maintenance regimens for cancer patients. van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059 [TBL] [Abstract][Full Text] [Related]
10. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255 [TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493 [TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218 [TBL] [Abstract][Full Text] [Related]
13. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579 [TBL] [Abstract][Full Text] [Related]
15. Suramin and serum insulin-like growth factor levels in metastatic cancer patients. Miglietta L; Barreca A; Repetto L; Costantini M; Rosso R; Boccardo F Anticancer Res; 1993; 13(6B):2473-6. PubMed ID: 8135485 [TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555 [TBL] [Abstract][Full Text] [Related]
17. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301 [TBL] [Abstract][Full Text] [Related]
18. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease. Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506 [No Abstract] [Full Text] [Related]
19. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555 [TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]